When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group)
✍ Scribed by Bruno Cassinat; Stéphane de Botton; Charikleia Kelaidi; Lionel Ades; Fabien Zassadowski; Isabelle Guillemot; Marie-Helene Schlageter; Emmanuel Raffoux; Jean-Luc Harousseau; Olivier Legrand; Martine Escoffre-Barbe; Oumedaly Reman; Martine Gardembas; Chantal Himberlin; Jean Yves Cahn; Denis Guyotat; Didier Bouscary; Anne Parry; Philippe Rousselot; Andre Baruchel; Hervé Dombret; Sylvie Chevret; Pierre Fenaux; Christine Chomienne
- Book ID
- 104040936
- Publisher
- Elsevier Science
- Year
- 2009
- Tongue
- English
- Weight
- 450 KB
- Volume
- 33
- Category
- Article
- ISSN
- 0145-2126
No coin nor oath required. For personal study only.
✦ Synopsis
10-20% of APL patients relapse and the challenge remains to early identify these patients to improve survival rate. We report PML-RARalpha transcript detection by RQ-PCR in 260 consecutive APL patients (n = 970 samples). 223 patients with samples of sufficient RNA quality to demonstrate they reached molecular remission were monitored for MRD. During follow-up, 38 of these patients were tested positive for PML-RARalpha mRNA. 13 out of the 38 patients (34%) effectively developed hematological relapse. In the first positive sample, specific PML-RARalpha NCN thresholds over which, or under which, patients could effectively be predicted to relapse or not, were identified and subsequently validated in a second cohort.